NetworkNewsBreaks Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report

NetworkNewsBreaks Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report

Feb 07, 2020 (MENAFN via COMTEX) —

(MENAFN – Investor Brand Network) Satsuma Pharmaceuticals (NASDAQ: STSA) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, ‘We are BUY rated on Satsuma given the potential we see for STS101 in the acute treatment of migraines. Phase 3 data is expected in 2H 2020, with regulatory filing in late 2021 and potential market entry in late 2022/early 2023. We see STS101 as a differentiated asset delivering dihydroergotaminemesylate (‘DHE’) intranasally that can be used by patients who do not respond to current treatment options. We estimate probability-adjusted sales of ~$300MM in 2028 along with a 70% probability of success.’

To request access to the full report, visit http://nnw.fm/SaZ9d

About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (‘DHE’), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds. The company believes STS101 would, if approved, be an attractive migraine treatment option for many patients and may enable a larger number of people with migraine to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical development, completed a Phase 1 clinical trial, and is currently in Phase 3 development. Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For more information,

Read More Here...

Bookmark the permalink.

Comments are closed.